Cvijic Christine Mikail 4
4 · Neurogene Inc. · Filed Jul 7, 2026
Research Summary
AI-generated summary of this filing
Neurogene (NGNE) President & CFO Christine Cvijic Sells 4,800 Shares
What Happened
- Christine Mikail Cvijic, President, Chief Financial Officer and a director of Neurogene Inc. (NGNE), sold a total of 4,800 shares in open-market transactions: 600 shares on 2026-07-06 at a weighted average price of $36.02 for $21,613, and 4,200 shares on 2026-07-07 at a weighted average price of $36.13 for $151,763. Total proceeds were approximately $173,376.
- These were sales (not purchases) executed under a pre-established Rule 10b5-1 plan, so they are generally routine and scheduled rather than ad hoc insider trades.
Key Details
- Transaction dates and prices:
- 2026-07-06: 600 shares at a weighted avg $36.02 (range reported $36.00–$36.035).
- 2026-07-07: 4,200 shares at a weighted avg $36.13 (range reported $36.00–$36.455).
- Shares owned after the transaction:
- The filing notes Cvijic no longer holds any shares jointly with her spouse following these sales.
- She retains unvested restricted stock units totaling 46,168 RSUs (10,635 vests 3/13/2027; 13,533 vest in equal installments on 3/26/2027 & 3/26/2028; 22,000 vest annually on 2/20/2027–2/20/2029).
- Notable footnotes:
- Sales were effected pursuant to a 10b5-1 trading plan adopted August 18, 2025 (F1).
- Reported prices are weighted averages; the filer can provide a breakdown of the number of shares sold at each specific price within the disclosed ranges (F2, F4).
- Timeliness: Report filed 2026-07-07 for transactions on 2026-07-06 and 2026-07-07 — consistent with standard Form 4 timing (not indicated as late).
Context
- Sales made under a 10b5-1 plan are typically prearranged and do not necessarily reflect the insider’s current view of the company. For retail investors, purchases by insiders tend to carry more informational weight than routine sales; these transactions appear to be scheduled disposals of jointly held shares.
Insider Transaction Report
Form 4
Neurogene Inc.NGNE
Cvijic Christine Mikail
DirectorPresident and CFO
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-07-06$36.02/sh−600$21,613→ 88,240 total - Sale
Common Stock
[F1][F4][F3]2026-07-07$36.13/sh−4,200$151,763→ 84,040 total
Footnotes (4)
- [F1]The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.035, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.455, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Signature
/s/ Donna M. Cochener as attorney-in-fact for Christine Mikail Cvijic|2026-07-07